Positive topline clinical results support streamlined development pathway for lpcn 1154, lipocine's oral candidate for rapid relief of depression

Identified dosing regimen that enables reliance on a single confirmatory pivotal pharmacokinetic (pk) study to establish efficacy for postpartum depression (ppd) and support nda submission lpcn 1154 treatment was well-tolerated with no hypoxia or sedation-related adverse events lipocine plans to initiate the confirmatory pivotal pk study in 2h 2023   conference call and webcast today at 8:30am et salt lake city , may 16, 2023 /prnewswire/ -- lipocine inc. (nasdaq: lpcn), today announced positive topline results from a pilot clinical pk bridge study of lpcn 1154 (oral brexanolone) with a comparator, iv brexanolone. the pilot study is an important step in lipocine's ongoing program to develop lpcn 1154 for ppd.
LPCN Ratings Summary
LPCN Quant Ranking